Lanreotide (diTFA)

• Description :

  Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome[1][2].

• Product Name Alternative :

  BIM 23014 (diTFA)

• UNSPSC :

  12352209

• Target :

  Somatostatin Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/lanreotide-ditfa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Formula :

  C58H71F6N11O14S2

• Molecular Weight :

  1324.37

• References & Citations :

  [1]Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16 (3) :1045-55.|[2]Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf) . 2003 Jul;59 (1) :115-28.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  Launched

• CAS Number :

  [1024499-83-9]